These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 39026240)
1. Fenofibrate's impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study. Hong S; Kim KS; Han K; Park CY Cardiovasc Diabetol; 2024 Jul; 23(1):263. PubMed ID: 39026240 [TBL] [Abstract][Full Text] [Related]
2. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. Toth PP; Philip S; Hull M; Granowitz C Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751 [TBL] [Abstract][Full Text] [Related]
4. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. Kim NH; Han KH; Choi J; Lee J; Kim SG BMJ; 2019 Sep; 366():l5125. PubMed ID: 31562117 [TBL] [Abstract][Full Text] [Related]
5. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP; JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716 [TBL] [Abstract][Full Text] [Related]
6. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M; Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551 [TBL] [Abstract][Full Text] [Related]
7. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC Eur J Prev Cardiol; 2024 Aug; 31(10):1205-1213. PubMed ID: 38408362 [TBL] [Abstract][Full Text] [Related]
8. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort. Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. Park SY; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC J Clin Endocrinol Metab; 2024 Jun; 109(7):1883-1890. PubMed ID: 38175670 [TBL] [Abstract][Full Text] [Related]
10. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Tenenbaum A; Fisman EZ Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659 [TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea. Lee J; Lee S Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928 [TBL] [Abstract][Full Text] [Related]
12. The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes. Andersson T; Nåtman J; Mourtzinis G; Bager JE; Bengtsson Boström K; Franzén S; Hjerpe P Eur J Prev Cardiol; 2023 Nov; 30(17):1883-1894. PubMed ID: 37368941 [TBL] [Abstract][Full Text] [Related]
14. Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. Kim KS; Hong S; Han K; Park CY Metabolism; 2022 Dec; 137():155327. PubMed ID: 36202222 [TBL] [Abstract][Full Text] [Related]
15. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. Fung CSC; Wan EYF; Chan AKC; Lam CLK BMC Cardiovasc Disord; 2017 Jun; 17(1):166. PubMed ID: 28645252 [TBL] [Abstract][Full Text] [Related]
16. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652 [TBL] [Abstract][Full Text] [Related]
17. The effect of change in fasting glucose on the risk of myocardial infarction, stroke, and all-cause mortality: a nationwide cohort study. Lee G; Kim SM; Choi S; Kim K; Jeong SM; Son JS; Yun JM; Park SM Cardiovasc Diabetol; 2018 Apr; 17(1):51. PubMed ID: 29626936 [TBL] [Abstract][Full Text] [Related]
18. Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy. Tada H; Nomura A; Yoshimura K; Itoh H; Komuro I; Yamagishi M; Takamura M; Kawashiri MA Circ J; 2020 Feb; 84(3):509-515. PubMed ID: 32023582 [TBL] [Abstract][Full Text] [Related]
19. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Soroush N; Nekouei Shahraki M; Mohammadi Jouabadi S; Amiri M; Aribas E; Stricker BH; Ahmadizar F Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2021-2033. PubMed ID: 38866619 [TBL] [Abstract][Full Text] [Related]